SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model

Trung The Van(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Shin‐ichi Akiyama(Nagoya University), Yasuhiko Nishioka(Tokushima University), Hisatsugu Goto(Tokushima University), Satoshi Sakaguchi(Tokushima University Hospital), Seidai Sato(Tokushima University), Masaki Hanibuchi(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Takuya Kuramoto(Tokushima University), Le Tan Dat(Tokushima University), Sawaka Yukishige(Tokushima University)
Respirology
May 11, 2012
10.1111/j.1440-1843.2012.02193.x
Cited by 16

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124